CDXC

ChromaDex Corporation

NASDAQ Capital Market

$1.81

Open: $1.98 High: $1.98 Low: $1.8 Close: $1.86

Range: 2022-06-27 - 2022-06-28

Volume:289,504

Market: Open

Get Free API Key

Download as Excel

CDXC

ChromaDex Corporation 10900 WILSHIRE BLVD https://www.chromadex.com

ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. It delivers Niagen as the sole active ingredient in its consumer product namely, Tru Niagen which is available on Tru Niagen's website and through partnerships with retailers and distributors.

CEO: Robert N. Fried
Employees: 115
Sector: Healthcare
Industry: Biotechnology

Latest Stocks Posts

View All Posts >

CDXC News

Latest news about the CDXC

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're closing in on the end of the week for trading as we go over the biggest pre-market stock movers for Friday!
by Investor Place at 5/20/22, 12:00 AMView More →
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's the start of another busy week of trading and we're kicking it off with a look at the biggest pre-market stock movers for Monday!
by Investor Place at 6/7/21, 12:00 AMView More →
CDXC Stock: Why ChromaDex Shares Are Rocketing Higher Today
Promising Phase III clinical results for Covid-19 treatment have investors falling over themselves to buy into ChromaDex stock.
by Investor Place at 2/25/21, 12:00 AMView More →
BRIEF-Chromadex And NIH-NIAID Rocky Mountain Laboratories Announce Study To Assess Therapeutic Potential Of Niagen® In Covid-19 Animal Models
* CHROMADEX AND THE NIH-NIAID ROCKY MOUNTAIN LABORATORIES ANNOUNCE STUDY TO ASSESS THE THERAPEUTIC POTENTIAL OF NIAGEN® IN COVID-19 ANIMAL MODELS
by Reuters at 7/7/20, 10:43 AMView More →
BRIEF-Chromadex Says May Offer & Sell Shares Of Common Stock Of Up To $50 Mln From Time To Time, Pursuant To Sales Agreement, Dated June 12, 2020
* CHROMADEX - MAY OFFER & SELL SHARES OF COMMON STOCK OF UP TO $50 MILLION FROM TIME TO TIME, PURSUANT TO SALES AGREEMENT, DATED JUNE 12, 2020 Source text: [https://bit.ly/3hZkcPI] Further company coverage: (Reuters.Briefs@thomsonreuters.com)
by Reuters at 6/26/20, 10:07 PMView More →
BRIEF-ChromaDex Says An R&D Facility In Colorado Earns Accredition
* CHROMADEX SAYS ITS RESEARCH AND DEVELOPMENT FACILITY IN LONGMONT, COLORADO ACHIEVED A QUALITY STANDARD FOR LABORATORY TESTING Source text for Eikon: Further company coverage:
by Reuters at 6/17/20, 12:52 PMView More →
BRIEF-Chromadex Corp Files For Mixed Shelf Of Up To $125 Million – SEC Filing
* CHROMADEX CORP FILES FOR MIXED SHELF OF UP TO $125 MILLION – SEC FILING Source text for Eikon: https://bit.ly/2XXggqT Further company coverage:
by Reuters at 6/12/20, 9:03 PMView More →
BRIEF-Chromadex Says Selling Stockholders Offer And Resale Of Up To 1.23 Mln Shares Of Common Stock
* CHROMADEX CORP SAYS SELLING STOCKHOLDERS OFFER AND RESALE OF UP TO 1.23 MILLION SHARES OF COMMON STOCK - SEC FILING Source: (https://bit.ly/3csPquD) Further company coverage:
by Reuters at 6/3/20, 1:01 PMView More →
7 Healthcare Stocks That Will Give You Chest Pains
Given the massive changes with Trumpcare, don’t get stuck with the wrong stocks. Sell these healthcare stocks immediately.
by Investor Place at 6/23/17, 12:00 AMView More →
CenturyLink Inc (CTL), Tripadvisor Inc (TRIP) Lead 17 Notable Investor Filings
CenturyLink (CTL), Gigamon (GIMO) and TripAdvisor (TRIP) are among the more notable investor filings out recently.
by Investor Place at 5/9/17, 12:00 AMView More →

S&P 500

NASDAQ 100

FTSE 100

QQQ

TESLA

BTC/USD

GBP/USD

GOLD